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Abstract
Background.—Cognitive impairment is a core feature of psychotic disorders, but the profile of 
impairment across adulthood, particularly in African-American populations, remains unclear.
Methods.—Using cross-sectional data from a case–control study of African-American adults 
with affective (n = 59) and nonaffective (n = 68) psychotic disorders, we examined cognitive 
functioning between early and middle adulthood (ages 20–60) on measures of general cognitive 
ability, language, abstract reasoning, processing speed, executive function, verbal memory, and 
working memory.
Results.—Both affective and nonaffective psychosis patients showed substantial and widespread 
cognitive impairments. However, comparison of cognitive functioning between controls and 
psychosis groups throughout early (ages 20–40) and middle (ages 40–60) adulthood also revealed 
age-associated group differences. During early adulthood, the nonaffective psychosis group 
showed increasing impairments with age on measures of general cognitive ability and executive 
function, while the affective psychosis group showed increasing impairment on a measure of 
language ability. Impairments on other cognitive measures remained mostly stable, although 
decreasing impairments on measures of processing speed, memory and working memory were 
also observed.
Conclusions.—These findings suggest similarities, but also differences in the profile of 
cognitive dysfunction in adults with affective and nonaffective psychotic disorders. Both affective 
and nonaffective patients showed substantial and relatively stable impairments across adulthood. 
The nonaffective group also showed increasing impairments with age in general and executive 
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functions, and the affective group showed an increasing impairment in verbal functions, possibly 
suggesting different underlying etiopathogenic mechanisms.
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Life-span; neuropsychology; psychosis; schizophrenia; trajectory
Introduction
Cognitive impairment is a core feature of psychotic disorders, manifesting before onset of 
symptoms (Jones et al., 1994; Davidson et al., 1999), persisting during illness remission 
(Addington and Addington, 1993; Brissos et al., 2011), and predicting multiple functional 
outcomes (Green et al., 2000; Fett et al., 2011). Studies of cognitive function in 
schizophrenia patients have almost unequivocally reported medium to large impairments 
across most cognitive domains (Fioravanti et al., 2005; Reichenberg and Harvey, 2007), but 
findings from studies of cognitive functioning in other psychosis patients have been more 
mixed, with evidence of similarities (Schatzberg et al., 2000; Fleming et al., 2004; Bora et 
al., 2009; Reichenberg et al., 2009; Zanelli et al., 2010) and differences (Mojtabai et al., 
2000; Glahn et al., 2006; MacCabe et al., 2013; Mollon et al., 2018) between diagnoses. 
Thus, the profile of cognitive impairment in affective and nonaffective psychosis diagnoses 
remains unclear.
Questions also remain regarding the course of cognitive impairment in psychotic disorders. 
There is evidence for cognitive decline between premorbid and post-onset stages of 
psychotic disorders (Seidman et al., 2006; Meier et al., 2013; Gur et al., 2014; Mollon et al., 
2018). However, both cross-sectional (Hyde et al., 1994; Chen et al., 1996; Mockler et al., 
1997; Fucetola et al., 2000) and longitudinal (Szöke et al., 2008; Bozikas and Andreou, 
2011; Samamé et al., 2014) studies have generally reported stabilization of impairments 
after illness onset, with some exceptions (Bilder et al., 1992; Davidson et al., 1995; Harvey 
et al., 1999; Friedman et al., 2001). However, previous studies examining the course of 
cognitive impairment after illness onset have several limitations. First, the length of follow-
up in longitudinal studies has been short, with few exceeding 2 years and even fewer 
exceeding 5 years. Second, many of these studies, particularly those with cross-sectional 
data, did not include control groups, making it difficult to establish whether age-associated 
cognitive changes reflect pathological processes or normal aging. Third, age has been 
categorized into broad periods, rather than investigated as a continuous factor, making it 
difficult to fully disentangle the effect of age on cognitive functioning. Fourth, the results 
regarding specific cognitive measures are mixed, with evidence for decline relative to 
controls on measures of executive function (Heilbronner et al., 2016), and visual and verbal 
memory (Gur et al., 1998; Albus et al., 2002; Burdick et al., 2006), but also stable 
processing speed impairments (Bonner-Jackson et al., 2010). Finally, studies on the course 
of cognitive impairment across adulthood have mostly focused separately on nonaffective 
psychotic disorders, such as schizophrenia, and affective psychoses, such as bipolar disorder. 
Therefore, knowledge regarding the similarities and differences between affective and 
nonaffective psychotic disorders in terms of the profile of cognitive impairment across 
adulthood remains scarce. Finally, the roles of potential confounders, such as antipsychotic 
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medications, cannabis use, and psychiatric comorbidity have not been comprehensively 
examined. Thus, the course of cognitive impairments across adulthood in psychotic 
disorders, particularly as pertaining to specific cognitive measures and diagnoses, remains 
uncertain.
In this study, we examined cognitive functioning in a population-based, case–control, cross-
sectional study of African-American adults with affective and nonaffective psychotic 
disorders. African-Americans are underrepresented in psychiatry research and there is a 
need for more data on cognitive functioning in adults with psychotic disorders from this 
population. The aims of the study were to (1) establish the profile of cognitive impairment in 
affective and nonaffective psychosis patients across early and middle adulthood (ages 20–
60), and (2) examine the effect of important potential confounders, including antipsychotic 
medication, cannabis use, psychiatric comorbidity, substance dependence, symptom severity, 
duration of psychosis, education, and functioning.
Methods
Subjects
All subjects were African-Americans from the Hartford area. Cognitive data were available 
for 134 patients with psychosis and 254 controls. The sample was determined from a data 
freeze on 17 January 2018, prior to any analyses presented herein, and reflects a subset of 
the planned sample for the study. Patients had various psychotic diagnoses, which are 
described below. Neither patients nor controls were excluded for having non-psychotic 
psychiatric disorders. Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV 
diagnoses were made using the Structured Clinical Interview for DSM-IV-TR Axis I 
Disorders (SCID) (First et al., 2002) and a consensus process (Glahn et al., 2007). Subjects 
with a history of major non-psychiatric medical disorders (history of strokes, HIV/AIDS, 
history of traumatic brain injury, epilepsy, hepatitis, chronic myelogenous leukemia, cancer, 
history of seizures, history of coma or unconsciousness, and severe tremors) or with an 
intelligence quotient of below 70 were excluded. All subjects provided informed consent. 
The review boards at Hartford Hospital and Yale University approved the study. Sample 
characteristics are provided in Table 1.
Cognitive functioning
Subjects completed a cognitive test battery (‘Charlie’, https://github.com/sammosummo/
Charlie). This cognitive battery has been described elsewhere (Mathias et al., 2017, 2018) 
and a summary of the measures is included in online Supplementary Table S1. These 
measures have been used extensively in prior research, so that their psychometric properties 
and cognitive demands are well understood. In addition to the measures directly indexed by 
the cognitive battery, we derived a general composite score (g) as the first component of 
principal component analyses using all cognitive tests. Correlations between all test scores 
can be seen in online Supplementary Fig. S1.
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The statistical programing language R (R Development Core Team, 2008) was used for all 
analyses. Due to the more limited number of patients younger than 20 years and older than 
60 years, we restricted analyses to individuals aged 20–60 years of age. Patients were 
categorized into two groups: (1) affective psychosis (n = 59), comprising diagnoses of 
schizoaffective disorder (n = 40), psychotic bipolar disorder (n = 12), and psychotic major 
depression (n = 7), and (2) nonaffective psychosis (n = 68), comprising diagnoses of 
schizophrenia (n = 56), psychosis not otherwise specified (n = 10), and brief psychotic 
disorder (n = 2). These patient groups were compared to controls in all subsequent analyses.
In order to examine group differences in cognitive functioning, as well as the effect of age 
on these differences, cross-sectional cognitive data from ages 20 to 60 were used to generate 
cognitive charts for each group and cognitive test. All test scores were trans-formed to z 
scores, with higher scores indicating better performance. Individual z scores adjusted for sex 
were subsequently used to calculate percentiles for each age stratum and 5-year sliding 
windows were applied to increase accuracy of percentile estimation (Buuren and Fredriks, 
2001; Vorstman et al., 2015). Online Supplementary Fig. S2 shows g charts for control, 
affective psychosis and nonaffective psychosis groups, which were generated by connecting 
percentiles using local regression smoothing.
Group differences in cognitive charts (i.e. 50th percentiles) were tested using regression 
analysis. Group and age effects, as well as group-by-age interactions were included in all 
models. Natural cubic splines (Smith, 1979; Lin and Zhang, 1999; Benedetti and 
Abrahamowicz, 2004) were used to model the non-linear effect of age on cognitive charts as 
illustrated in online Supplementary Fig. S3, which shows cognitive charts for control, 
affective psychosis, and nonaffective psychosis groups with local regression smoothing 
(Buuren and Fredriks, 2001). Alternative models were evaluated with the Akaike 
information criterion (AIC) (Akaike, 1992) and Bayesian information criterion (BIC) 
(Schwarz, 1978) fit indices, which are information theory based statistics useful for 
comparing the relative fit of several models. Models with lower AIC and BIC values are 
thought to be relatively better fitting. Online Supplementary Table S2 shows AIC and BIC 
indices of these alternative models, indicating that a model with age as a natural cubic spline 
with three knots (i.e. one internal knot at median age 40 years and two boundary knots at 
ages 20 and 60) was a better fit to the data than a model with age as a linear function. 
Moreover, a model with age as a natural cubic spline with three knots was also a better fit 
than a model with age as a natural cubic spline with four knots [i.e. two internal knots at the 
33rd (age = 34) and 66th (age = 46) percentiles, and two boundary knots at ages 20 and 60]. 
Finally, a model with group and age effects, as well as a group-by-age interaction, was a 
better fit than a model with only group and age effects. Thus, all models included group and 
age effects, as well as group-by-age interactions, and age as a natural cubic spline with three 
knots. Modeling age as a natural cubic spline with three knots (i.e. one internal knot at 
median age 40 years and two boundary knots at ages 20 and 60) enabled examination of 
group-by-age interactions on cognitive charts in early adulthood (i.e. between ages 20 and 
40), as well as middle adulthood (i.e. between ages 40 and 60).
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In order to examine the effect of potential confounders, individual test scores were 
subsequently adjusted for (1) antipsychotic medication, (2) cannabis use, (3) psychiatric 
comorbidity (i.e. number of non-psychotic psychiatric diagnoses), (4) current substance 
dependence, (5) lifetime substance dependence (i.e. including remitted substance 
dependence), (6) severity of psychotic symptoms as measured by the Lifetime Dimensions 
of Psychosis Scale (LDPS) (Levinson et al., 2002), (7) duration of psychosis, (8) education, 
(9) maternal education, (10) employment in the past year, (11) general functioning as 
measured by the Global Assessment of Functioning (GAF) scale (Hall, 1995) and (12) social 
functioning. Individual test scores were also adjusted for sex. These adjusted scores were 
then used to generate cognitive charts as described above. To control for multiple testing, the 
false discovery rate (FDR) was set at 5% (Benjamini and Yekutieli, 2001).
Results
Affective and nonaffective psychosis patients show widespread cognitive impairments
Figure 1 depicts effect sizes (ESs) of overall cognitive impairment for the affective and 
nonaffective psychosis groups, and Table 2 shows group effects on each cognitive chart for 
the affective and nonaffective psychosis groups. Since cognitive test scores were z 
transformed, β coefficients correspond to standardized ESs, with values of 0.2, 0.5 and 0.8 
indicating small, medium and large ESs, respectively (Cohen, 1992). The nonaffective 
psychosis group showed statistically significant impairments on all cognitive measures, with 
a large g impairment (β = −0.82, p < 0.001), medium impairments on the Wechsler Test of 
Adult Reading (WTAR) (β = −0.67, p < 0.001), semantic fluency (β = −0.45, p <0.001), 
Trail-Making A and B (β = −0.60, p < 0.001; β = −0.61, p < 0.001), digit-symbol coding (β 
= −0.63, p < 0.001), California Verbal Learning Test (CVLT) recall and recognition (β = 
−0.50, p < 0.001 and β = −0.43, p < 0.001), digit span forward and backward (β = −0.57, p < 
0.001; β = −0.46, p < 0.001), and letter-number sequencing (β = −0.65, p < 0.001), and 
small impairments on vocabulary (β = −0.27, p < 0.001) and matrix reasoning (β = −0.29, p 
< 0.001). All impairments remained statistically significant after FDR correction.
The affective psychosis group showed statistically significant impairments on all cognitive 
measures, except matrix reasoning, and span forward and backward, with medium 
impairments on g (β = −0.46, p < 0.001), WTAR (β = −0.45, p < 0.001), semantic fluency (β 
= −0.44, p < 0.001), Trail-Making A (β = −0.43, p <0.001), digit-symbol coding (β = −0.44, 
p < 0.001), CVLT recall (β = −0.54, p < 0.001) and letter-number sequencing (β = −0.44, p 
< 0.001), and small impairments on vocabulary (β = −0.19, p = .013), verbal fluency (β = 
−0.15, p = .013), Trail-Making B (β = −0.31, p < 0.001), and CVLT recognition (β = −0.35, 
p <0.001). All impairments remained statistically significant after FDR correction. While the 
nonaffective psychosis group showed larger impairments than the affective psychosis group 
on all measures except CVLT recall, these differences were small, with only differences on 
span forward and backward reaching a magnitude of medium ES (Fig. 1).
Cognitive charts in early adulthood
Figure 2 shows cognitive charts for control, affective psychosis and nonaffective psychosis 
groups. Age-associated decline was apparent in all groups and in all cognitive measures. 
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However, age-associated group differences were also observed. Table 2 shows group-by-age 
interactions and ESs on each cognitive chart during early (i.e. between ages 20 and 40) and 
late (i.e. between ages 40 and 60) adulthood for affective and nonaffective psychosis groups. 
During early adulthood, the nonaffective psychosis group showed increasing impairments on 
Trail-Making B (β = −1.54, p = 0.006), and g (β = −0.84, p = 0.019), although the latter did 
not reach statistical significance after FDR correction. As illustrated in Fig. 2, the 
nonaffective psychosis group showed no impairment on Trail-Making B at age 20 (0.02 S.D. 
above controls), but a large impairment had emerged by age 40 (0.87 S.D. below controls), 
indicating an increase in deficit of 0.89 S.D. The g impairment increased from 0.49 S.D. at age 
20 to 1.09 at age 40, indicating an increase in deficit of 0.60 S.D.
Similarly, the affective psychosis group showed an increasing impairment during early 
adulthood on vocabulary (β = −0.92, p = 0.026), although this did not reach statistical 
significance after FDR correction. As seen in Fig. 2, the affective psychosis group did not 
show a vocabulary impairment at age 20 (0.18 S.D. above controls), but by age 40 a medium 
impairment (0.45 S.D. below controls) had emerged, indicating an increase in deficit of 0.63 
S.D. On the other hand, the affective psychosis group showed a decreasing impairment during 
early adulthood on CVLT recall (β = 1.34, p = 0.001), so that the impairment decreased from 
1.11 S.D. to 0.51 S.D. between ages 20 and 40, indicating a decrease in deficit of 0.60 S.D.
Cognitive charts in middle adulthood
During middle adulthood (i.e. between ages 40 and 60), both the affective and nonaffective 
psychosis groups showed decreasing impairments on WTAR (affective: β = 1.36, p < 0.001; 
nonaffective: β = 0.82, p = 0.002), semantic fluency (affective: β = 1.17, p < 0.001; 
nonaffective: β = 0.61, p = 0.026) and CVLT recall (affective: β = 0.77, p < 0.001; 
nonaffective: β = 1.28, p < 0.001) (Table 2). Additionally, the affective psychosis group 
showed a decreasing impairment on the digit-symbol coding (β = 0.54, p = 0.003), and the 
nonaffective psychosis group on g (β = 0.60, p = 0.007), vocabulary (β = 0.81, p = 0.002), 
and span forward (β = 1.17, p = 0.002). In all cases, cognitive impairments present at age 40 
were negligible or no longer present at age 60 (Fig. 2).
Group-by-age interactions in early and middle adulthood on verbal fluency, Trail-Making A, 
CVLT recognition, and letter-number sequencing were non-significant for both groups, 
suggesting stable deficits on these measures throughout adulthood. The affective psychosis 
group also showed a stable g impairment throughout adulthood, and the nonaffective group 
showed stable matrix reasoning and span backward deficits. Table 3 summarizes cognitive 
impairments across early and middle adulthood for both psychosis groups.
Confounders do not account for cognitive impairments or deviations in cognitive charts
Online Supplementary Tables S3–S14 show group and group-by-age interaction effects after 
adjustment for potential confounders. Results were similar when adjusting for antipsychotic 
medication, cannabis use, psychiatric comorbidity, and both current and lifetime substance 
dependence (online Supplementary Tables S3–S7). The nonaffective psychosis group 
showed small to large cognitive impairments and an increasing impairment on Trail-Making 
B during early adulthood. The affective psychosis group showed small to medium 
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impairments, and both groups showed decreasing impairments on several measures during 
middle adulthood.
When adjusting for severity of psychotic symptoms (online Supplementary Table S7), the 
nonaffective psychosis group showed small cognitive impairments and an increasing 
impairment on Trail-Making B during early adulthood, but impairments in the affective 
psychosis group were attenuated. When adjusting for duration of psychosis (online 
Supplementary Table S8), the increasing impairment on Trail-Making B during early 
adulthood in the nonaffective psychosis group no longer reached statistical significance and 
the affective psychosis group showed only a small impairment on CVLT recall. However, 
duration of psychosis and age are correlated (online Supplementary Fig. S4), making it 
difficult to disentangle their effects.
Both groups showed small to medium impairments when adjusting for education (online 
Supplementary Table S9) and decreasing impairments on several measures during middle 
adulthood. Interestingly, the increasing impairment on Trail-Making B during early 
adulthood in the nonaffective psychosis group no longer reached statistical significance, but 
the affective psychosis group showed a significantly increasing impairment on vocabulary 
and verbal fluency during this period. However, the causal nature of the relationship between 
education and cognition is complex, making these results challenging to interpret. Adjusting 
for maternal education, on the other hand, attenuated the increasing impairment on 
vocabulary in the affective group, but the nonaffective group showed increasing impairments 
on Trail-Making B and letter number sequencing (online Supplementary Table S11).
When adjusting for employment, both groups showed small cognitive impairments across 
adulthood and decreasing impairments on several measures during middle adulthood (online 
Supplementary Table S12). The affective psychosis group showed an increasing impairment 
on vocabulary during early adulthood, and the nonaffective group showed increasing 
impairments on g and Trail-Making B. Adjusting for general functioning attenuated 
impairments on most cognitive measures across adulthood in both the affective and 
nonaffective groups (online Supplementary Table S13), but the nonaffective group still 
showed an increasing impairment on Trail-Making B in early adulthood. On the other hand, 
impairments across adulthood remained small to large in both groups when adjusting for 
social functioning (online Supplementary Table S14), but the increasing impairment on 
Trail-Making B during early adulthood in the nonaffective group no longer reached FDR-
corrected significance.
Discussion
Using cross-sectional data from a population-based, case–control, adult sample of African-
American psychosis patients, we found substantial and widespread cognitive impairments, in 
line with an expansive literature on cognitive dysfunction in psychotic disorders (Fioravanti 
et al., 2005; Glahn et al., 2007; Reichenberg and Harvey, 2007; Bora et al., 2009). Both 
affective and nonaffective psychosis patients showed impairments on measures of general 
cognitive ability, language, abstract reasoning, processing speed, executive function, verbal 
memory and working memory, but the nonaffective group showed somewhat larger 
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impairments on almost all cognitive measures. Examining cognitive charts throughout 
adulthood also revealed age-associated group differences. Specifically, the nonaffective 
psychosis group showed increasing impairments on g and Trail-Making B during early 
adulthood (between ages 20 and 40). The affective psychosis group showed an increasing 
impairment on vocabulary during this period. Impairments on other cognitive measures 
remained mostly stable, although decreasing impairments on measures of processing speed, 
memory and working memory were also observed, mostly in middle adulthood (between 
ages 40 and 60). These findings add to knowledge about the profile of cognitive dysfunction 
across adulthood in psychotic disorders in several ways.
First, we found that the nonaffective psychosis group showed larger impairments than the 
affective psychosis group across all cognitive measures except for verbal memory recall. 
These differences were generally small, however, with only differences on span forward and 
backward reaching a magnitude of medium ES. Previous studies have also reported small 
differences in the magnitude of cognitive impairment between psychotic disorders (Bora et 
al., 2009; Zanelli et al., 2010). Our findings lend support to the notion that differences in 
cognitive impairment between affective and nonaffective psychotic disorders are more 
quantitative than qualitative (Reichenberg et al., 2009) since both affective and non-affective 
psychosis groups showed a similar profile of impairment, with decrements across most 
cognitive measures. Interestingly, the affective psychosis group did not show impairments on 
the digit span forward and backward, measures of working memory. Differential working 
memory impairments in affective and nonaffective psychotic disorders have been reported 
previously, albeit on measures of spatial rather than verbal working memory (Gooding and 
Tallent, 2002; Pirkola et al., 2005; Glahn et al., 2006). Nevertheless, working memory 
impairments may represent a somewhat specific vulnerability to nonaffective psychosis.
Second, examining cognitive charts across early and middle adulthood in affective and 
nonaffective psychosis patients revealed differences between groups, as well as cognitive 
measures. Specifically, the nonaffective psychosis group showed increasing impairments on 
g and Trail-Making B during early adulthood. The affective psychosis group showed an 
increasing impairment on vocabulary during early adulthood. While evidence suggests that 
psychosis patients exhibit cognitive decline between premorbid and post-onset periods of 
illness (Seidman et al., 2006; Meier et al., 2013; Mollon et al., 2018), studies have mostly 
reported stable cognitive impairments throughout adulthood (Hyde et al., 1994; Chen et al., 
1996; Mockler et al., 1997; Fucetola et al., 2000; Szöke et al., 2008; Bozikas and Andreou, 
2011; Samamé et al., 2014). Our findings suggest that, for certain cognitive measures, 
impairments may continue to increase during early adulthood. Increasing impairments on g 
and Trail-Making B in nonaffective psychosis patients are in line with evidence that 
impairments in these domains constitute some of the largest in schizophrenia (Reichenberg 
and Harvey, 2007). Moreover, previous studies have also reported increasing impairment in 
some measures of executive function during early adulthood (Fucetola et al., 2000; 
Heilbronner et al., 2016). The increasing impairment in vocabulary seen in the affective 
psychosis group, on the other hand, suggests that this and other language measures may be a 
poor indicator of premorbid cognitive ability. Nevertheless, impairments on the majority of 
cognitive measures remained static throughout adulthood with stable impairments on 
measures of processing speed, verbal memory and working memory throughout adulthood, 
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again, suggesting a similar profile of impairment across psychotic disorders. Interestingly, 
we found that both patient groups showed decreasing impairments on measures of general 
cognitive ability, language, processing speed, memory and working memory, particularly 
during middle adulthood. For the most part, these effects reflect acceleration of age-
associated differences in controls v. stabilization in patients, which is in line with evidence 
of age-associated cognitive decline in the general population well before late adulthood 
(Salthouse, 2009; Singh-Manoux et al., 2012; Hartshorne and Germine, 2015; Siman-Tov et 
al., 2016). However, whether this stabilization in patients continues to later adulthood 
warrants further investigation since there is evidence for further cognitive decline in older 
adults with psychotic disorders (Harvey et al., 1999; Friedman et al., 2001; Rajji and 
Mulsant, 2008).
Third, we examined the effect of a number of potential con-founders and found that, for the 
most part, these factors could not account for the differences across groups and cognitive 
measures. Overall impairments remained significant across most cognitive measures in the 
nonaffective psychosis group when adjusting for antipsychotic medication, cannabis use, 
psychiatric comorbidity, duration of psychosis, education, maternal education, employment, 
and social functioning. Overall impairments in the affective psychosis group showed greater 
attenuation by these factors, but remained significant across most cognitive measures when 
adjusting for antipsychotic medication, cannabis use and education. Overall impairments in 
both psychosis groups showed greatest attenuation when adjusting for symptom severity and 
general functioning, although the increasing impairment on Trail-Making B in the 
nonaffective group and increasing impairment on vocabulary in the affective group remained 
significant. Duration of psychosis was the only factor to attenuate increasing impairments in 
both psychosis groups, likely due to the fact that duration of psychosis and age are 
correlated. Nevertheless, our findings are in line with evidence that cognitive dysfunction, 
particularly in non-affective psychotic disorders, cannot be explained by antipsychotic 
medications (Mohamed et al., 1999; Hill et al., 2004), cannabis use (Løberg and Hugdahl, 
2009; Yucel et al., 2012), and symptom severity (Aleman et al., 1999; O’Leary et al., 2000). 
Moreover, while there is substantial evidence for psychiatric comorbidity and substance 
dependence in psychotic disorders (Mueser et al., 1992; Cassano et al., 1998; Buckley et al., 
2008), few studies have examined their effects on cognitive dysfunction (Pencer and 
Addington, 2003; McGurk et al., 2009; D’Souza and Markou, 2012). While our findings 
suggest that cognitive impairment, particularly in non-affective psychotic dis-order, cannot 
be broadly explained by psychiatric comorbidity, and both current and lifetime substance 
dependence, more research on the cognitive correlates of specific comorbidities, such as 
depression and alcohol dependence, is warranted. Similarly, while we were able to examine 
the effect of current antipsychotic medications on cognitive impairment, future studies on 
the effect of lifetime medications would be informative, particularly since a substantial 
proportion of psychotic patients use different and even multiple antipsychotics throughout 
the course of the illness (Stahl and Grady, 2004; Gallego et al., 2012).
This study has some limitations. First, the cognitive charts were calculated using cross-
sectional data, and replication with longitudinal data is needed. However, there are obvious 
challenges and pitfalls to collecting longitudinal data, especially spanning several decades, 
and length of follow-up in longitudinal studies has so far been limited to 10 years (Bozikas 
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and Andreou, 2011). Moreover, we adjusted for several potential confounders, including 
education and antipsychotic medication. Nevertheless, future examination of the influence of 
other potential cohort factors, such as health and environment, is needed. Second, our 
sample comprises African-American adults, and replication in samples of other ethnicities is 
required. However, African-Americans, like other minority groups, are underrepresented in 
psychiatry research, and were specifically chosen as the study population for this reason. 
Third, while our study advances knowledge regarding the cognitive profile of affective and 
nonaffective psychoses across adulthood, we were not able to subdivide these groups further 
to examine the profile of cognitive impairment in specific disorders, such as psychotic major 
depression. Fourth, due to the limited number of participants aged younger than 20 and older 
than 60, we were not able to examine age-associated differences in cognitive functioning 
beyond this age range. In the general population, cognitive changes are more likely to occur 
after the age of 65 (Czaja et al., 2006; Deary et al., 2009) and indeed there is evidence for 
further cognitive decline in older adults with psychotic disorders (Harvey et al., 1999; 
Friedman et al., 2001; Rajji and Mulsant, 2008). Finally, cognitive impairments in this study 
were somewhat smaller than those reported in the literature, possibly due to the fact that 
neither patients nor controls were excluded for having non-psychotic psychiatric disorders. 
Nevertheless, since psychiatric comorbidity is prevalent in psychotic disorders, our findings 
add valuable insight into cognitive dysfunction in psychosis.
In conclusion, we found substantial and widespread cognitive impairments across measures 
of general cognitive ability, language, abstract reasoning, processing speed, executive 
function, verbal memory and working memory in adults with both affective and nonaffective 
psychotic disorders. Moreover, during early adulthood, the nonaffective psychosis group 
showed increasing impairments on measures of general cognitive ability and executive 
function, while the affective psychosis group showed an increasing impairment in language 
ability. On most cognitive measures, however, impairments remained relatively stable 
throughout adulthood. Results remained largely unchanged when adjusting for antipsychotic 
medication, cannabis use, psychiatric comorbidity, substance dependence, symptom severity, 
duration of psychosis and education. Our findings extend previous knowledge regarding the 
profile of cognitive dysfunction across adulthood in affective and nonaffective psychotic 
disorders, suggesting both similarities and differences across groups and measures, as well 
as static and dynamic impairments. Different underlying etiopathogenic mechanisms may 
underlie the divergent cognitive impairments seen in affective and nonaffective psychosis.
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ES of overall impairment on each cognitive measure for affective and nonaffective psychosis 
groups.
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Cognitive charts for control, affective psychosis and nonaffective psychosis groups.
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